Suzanne Hodgkinson

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

C-terminal truncations in human 3′-5′ DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy

Anna Richards, Arn M. J. M. van den Maagdenberg, Joanna C. Jen et al. · Nature Genetics · 2007 · 452 citations

Life Sciences, Genetics, Molecular Biology +8

Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis

D. H. Miller, Paul S. Albert, Frederik Barkhof et al. · Annals of Neurology · 1996 · 444 citations

Medicine, Neurology, Radiology +14

Defining secondary progressive multiple sclerosis

Johannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis et al. · Brain · 2016 · 416 citations · Full text

Life Sciences, Neurology, Neuroscience +12

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled MR-monitored phase II trial

Bob W. van Oosten, Mitchell K.P. Lai, Suzanne Hodgkinson et al. · Neurology · 1997 · 268 citations

Life Sciences, Immunology, Neurology +15